Tenatoprazole

Tenatoprazole

Tenatoprazole

Chemical compound

Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]: 22 

Quick Facts Clinical data, Routes ofadministration ...

Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]: 27  and again in 2012.[3]: 17 

Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]

See also

References

  1. [1]
    "Gastrointestinal Disease Update". Digestive Disease Week. DataMonitor. March 2003.
  2. [2]
    "Investors unwilling to forgive Wockhardt, promoter for failings". Economic Times. 3 March 2011.
  3. [3]
    "State of New Product Development" (PDF). Mitsubishi Tanabe Pharma. 8 May 2012.
  4. [4]
    "FY2007 Interim Financial Results". Mitsubishi Tanabe Pharma.
  5. [5]
    Li H, Meng L, Liu F, Wei JF, Wang YQ (January 2013). "H+/K+-ATPase inhibitors: a patent review". Expert Opinion on Therapeutic Patents. 23 (1): 99–111. doi:10.1517/13543776.2013.741121. PMID 23205582. S2CID 44647770.
Share this article:

This article uses material from the Wikipedia article Tenatoprazole, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.